On February 28th, Jinshi Data reported that Sanyuan Biotechnology announced that the company and relevant responsible persons received the "Order for Correction Decision" and "Warning Letter Decision" from the Shandong Securities Regulatory Bureau. Upon investigation, it was found that when the company conducted impairment testing on long-term equity investments at the end of 2023, there were issues such as insufficient basis for selecting indicators like revenue growth rate, net operating asset growth rate, and discount rate, inappropriate selection of some indicators, and failure to consider the proportion of equity held, which violated relevant accounting standards and information disclosure management measures. The Shandong Securities Regulatory Bureau decided to take corrective measures against the company and issued warning letters to Chairman Nie ZaiJian, General Manager Cheng BaoHua, and Chief Financial Officer Yu JunLing
